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Predictors of GBV-C infection among patients referred for renal
transplantation. The etiology of liver disease remains unknown in about 4
to 23% of dialysis patients and 10 to 16% of renal transplant recipients. A
search for other causative agents of liver disease led to the discovery of the
GB group of viruses. We studied the association between the presence of
GB virus C (GBV-C) infection, known risk factors for parenterally-
transmitted infections and history or laboratory evidence of liver disease
among end-stage renal disease (ESRD) patients referred for renal trans-
plantation to the New England Organ Bank, MA. Stored sera from
patients on the renal transplantation waiting list between November 1986
and June 1990 were tested for antibody to hepatitis C virus (HCV). Sera
were available in 1544 of 3243 (48%) patients, and anti-HCV was detected
by ELISA3 in 287 (19%). All 287 anti-HCV positive patients formed the
anti-HCV positive cohort and 286 randomly selected anti-HCV negative
patients formed the anti-HCV negative cohort (573 patients overall).
Additional sera were available for GBV-C RNA testing in 465 of 573
(81%) patients, and GBV-C RNA was detected by RT-PCR in 146. The
overall extrapolated prevalence of serum GBV-C RNA was 29%. The
prevalence of serum GBV-C RNA among anti-HCV positive patients
(35%) was not significantly different from that among anti-HCV negative
patients (29%; P 5 0.22). In a univariate analysis, compared to patients
without GBV-C RNA, patients with serum GBV-C RNA were younger
[odds ratio (OR) 0.98 per year of age, P 5 0.01], had a lower proportion
of males (OR 0.64, P 5 0.03), lower proportion of patients with diabetes
mellitus (OR 0.44, P 5 0.01), higher proportion of patients with a previous
transplantation (OR 1.53, P 5 0.04), longer duration of dialysis at the time
of enrollment (OR 1.004 per month on dialysis, P 5 0.03), and a higher
proportion of patients with history of transfusions (OR 4.58, P 5 0.01).
Serum GBV-C RNA was not associated with a significantly increased OR
for history of liver disease or non-A, non-B hepatitis, or elevated serum
alanine aminotransferase levels. In a step-wise multivariate regression
analysis, a younger age (OR 0.98 per year of age, P 5 0.03), and history of
blood transfusions (OR 3.89, P 5 0.03) were associated with an increased
OR for serum GBV-C RNA, while diabetes mellitus was associated with
a decreased OR for GBV-C RNA (OR 0.47, P 5 0.01). Anti-HCV was not
a predictor of serum GBV-C RNA (OR 1.07, P 5 0.77). The results of this
study support the fact that GBV-C is a parenterally transmitted virus and
shed light on the modes of transmission of GBV-C among ESRD patients.
However, the association with liver disease remains to be established.
Liver disease is a major cause of morbidity and mortality among
patients with end-stage renal disease (ESRD). The major causes
of chronic liver disease in these patients include hepatitis B virus
(HBV), hepatitis C virus (HCV), alcohol and hemosiderosis [1].
However, the etiology of liver disease remains unknown in about
4 to 23% of dialysis patients [2–6] and 10 to 16% of renal
transplant recipients [7–10]. Likewise, among patients with com-
munity-acquired hepatitis, the etiology has remained elusive in
about 10 to 20% [11]. A search for other causative agents of liver
disease led to the discovery of the GB group of viruses [12, 13].
The GB group of viruses consist of GB viruses A, B and C.
While GB virus A (GBV-A) and GB virus B (GBV-B) are animal
viruses, GB virus C (GBV-C) is a human virus [12–14]. GBV-C is
an RNA virus belonging to the family Flaviviridae, and is closely
related to HCV [14, 15]. Further, the recently cloned hepatitis G
virus (HGV) [16] and the GBV-C are believed to be variants of
the same virus [17]. The prevalence of GBV-C is 0.8 to 2% among
volunteer blood donors [16, 18–20]. In contrast, the prevalence of
GBV-C is 3 to 58% among hemodialysis patients [18, 21–24], 4 to
18% among patients with hemophilia [16, 25, 26], 8.3% among
cadaver organ donors [27], and 16 to 33% among intravenous
drug users [16, 19, 20]. The high prevalence of GBV-C infection
among patient populations at high-risk of acquiring parenterally-
transmitted infections suggests that GBV-C is parenterally-trans-
mitted. However, the disease potential of GBV-C is as yet
undefined. Although the GB group of viruses were originally
isolated from a surgeon with hepatitis that could not be attributed
to a known agent [12, 13], a clear cause and effect relationship
between GBV-C and liver disease has not been established [28,
29]. Further, it is not clear whether it is indeed a hepatotropic
virus [30]. Therefore, we studied the association between the
presence of GBV-C infection, known risk factors for parenterally-
transmitted infections, and history or laboratory evidence of liver
disease among ESRD patients referred for renal transplantation.
METHODS
Patients
We used a cohort of patients previously selected to study the
effect of HCV infection and transplantation on patients with
end-stage renal disease referred for renal transplantation. The
details of patient selection are reported elsewhere [31]. Briefly,
1 See Editorial by Oldach, p. 1810
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patients were referred for renal transplantation to the 14 trans-
plant centers served by the New England Organ Bank (NEOB).
The first available serum sample from patients on the renal
transplant waiting list between November 1986 and January 1987
(“prevalent” population), as well as those referred for renal
transplantation between February 1987, and June 1990 (“inci-
dent” population) were retrieved from the Tissue Typing Labo-
ratory of the NEOB. Serum was available for anti-HCV testing in
394 of 655 (60%) prevalent patients and in 1150 of 2588 (44%)
incident patients. A control group of anti-HCV negative patients
was randomly selected in a 1:1 ratio for the prevalent and incident
cohorts separately. Of the 573 (287 anti-HCV positive and 286
anti-HCV negative) patients, additional serum was available for
GBV-C RNA testing in 465 patients, which comprised the sample
for this study.
Tests for Anti-HCV and GBV-C RNA
Serum samples, stored at 270°C at the NEOB, and the Tissue
Typing Laboratories at Brigham and Women’s Hospital, Massa-
chusetts General Hospital, and Maine Medical Center were
retrieved for testing. Serum samples were tested for GBV-C RNA
at Abbott Laboratories (North Chicago, IL, USA). Anti-HCV was
detected using the third generation ELISA (Orthoy HCV
ELISA3.0 Test System; Ortho Diagnostics System, Raritan, NJ,
USA) [31]. GBV-C RNA was detected by RT-PCR with primers
derived from the highly conserved 59UTR region of the GBV-C
genome [24, 27].
Clinical information
Clinical data were collected from the NEOB records, United
Network for Organ Sharing Computer Services, databases of the
Tissue Typing Laboratories of Brigham and Women’s Hospital,
Massachusetts General Hospital, and Maine Medical Center, and
hospital, transplant office and dialysis unit medical records at the
participating centers. The date of serum sample tested was
defined as the date of enrollment, and all patients in whom a
serum sample was available were enrolled into the study. Clinical
information collected at the time of enrollment included age,
gender, race, history of liver disease and non-A, non-B hepatitis
(NANBH), presence of diabetes mellitus, number of previous
transplants, modes of dialysis, year of initiation of dialysis, dura-
tion of renal replacement therapy, date of listing for renal
transplantation at the NEOB, blood transfusions, hepatitis B
surface antigen (HBsAg), antibody to hepatitis B surface antigen
(anti-HBs), antibody to hepatitis B core antigen (anti-HBc) and
antibody to cytomegalovirus (anti-CMV), serum alanine amino-
transferase (ALT) level, serum albumin level, blood group and
panel reactive antibody (PRA) assay. Duration of renal replace-
ment therapy was calculated from the date of initiation of dialysis
(or previous transplantation, whichever was earlier) to the date of
enrollment. Serum ALT was considered abnormal if it was greater
than two and a half times the upper limit of normal for the given
laboratory.
Statistical methods
The prevalence of GBV-C RNA among patients referred for
renal transplantation was calculated using methods previously
used in determining the prevalence of markers of HCV infection
among cadaver organ donors [32]. Since the anti-HCV positive
samples in this study represented all the anti-HCV positive
samples, but the anti-HCV negative controls represented only a
sample of the anti-HCV negative samples, we used the following
formulae to calculate the prevalence of GBV-C RNA
GBV-C RNA prevalence 5 K/N (Eq. 1)
K 5 A*B 1 C*D (Eq. 2)
where: K is the extrapolated number of test positive samples; N is
the total population (anti-HCV positive 1 anti-HCV negative
patients); A is the number of GBV-C RNA positive samples
among anti-HCV positive samples tested; B is the ratio of the
number of anti-HCV positive samples to the number of anti-HCV
positive samples tested for GBV-C RNA; C is the number of
GBV-C RNA positive samples among anti-HCV negative samples
tested; and D is the ratio of the number of anti-HCV negative
samples to the number of anti-HCV negative samples tested for
GBV-C RNA. The extrapolated prevalence of serum GBV-C
RNA was calculated separately for the prevalent and incident
groups, and the overall extrapolated prevalence was calculated as
follows:
Overall extrapolated prevalence 5 ~K1 1 K2!/~N1 1 N2!
(Eq. 3)
where K1 and K2 are the K, and N1 and N2 are the N for the
prevalent and incident populations, respectively, from equation 1.
The association between the presence of serum GBV-C RNA
and the clinical and laboratory variables listed above was exam-
ined using univariate logistic regression analysis. The odds ratio
(OR) for each variable was calculated, both unadjusted and
adjusted for the presence of anti-HCV. Two-way interaction
between anti-HCV and each variable was also tested. A step-wise
algorithm was used to build a multivariate logistic regression
model to examine the association between clinical/laboratory
variables and the presence of serum GBV-C RNA. Variable
selection proceeded as follows: (1) Variables with large amount of
missing data were initially excluded. (2) Factors that were signif-
icantly associated with serum GBV-C RNA (P , 0.05) in the
univariate analysis were included using step-wise selection pro-
cess, with the most significant variable being selected first. (3)
Anti-HCV was forced into all models. (4) The variables with large
amounts of missing data, but considered important were included
in the final model. All analysis were performed using SAS System
for windows version 6.10 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Prevalence of GBV-C RNA
Anti-HCV was detected in 139 of 394 (35%) prevalent patients,
148 of 1150 (13%) incident patients (P 5 0.001), and 287 of 1544
(19%) patients overall (Table 1). All 287 anti-HCV positive
patients formed the anti-HCV positive cohort and 286 randomly
selected anti-HCV negative patients formed the anti-HCV nega-
tive cohort (573 patients overall). These results have been previ-
ously reported [31]. Additional sera were available for GBV-C
RNA testing in 465 of 573 (81%) patients, and GBV-C RNA was
detected in 146. The overall extrapolated prevalence of serum
GBV-C RNA was 29%. The extrapolated prevalence of serum
GBV-C RNA among prevalent patients (33%) was not signifi-
cantly different from that among incident patients (28%; P 5
0.09). Likewise, the prevalence of serum GBV-C RNA among
anti-HCV positive patients (35%) was not significantly different
from that among anti-HCV negative patients (29%; P 5 0.22).
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Clinical and laboratory characteristics of patients with and
without serum GBV-C RNA
Univariate analysis. The results of univariate logistic regression
analysis, unadjusted for the presence of anti-HCV, are shown in
Table 2. Compared to patients without GBV-C RNA, patients
with serum GBV-C RNA were younger (OR 0.98 per year of age,
P 5 0.01), had a lower proportion of males (OR 0.64, P 5 0.03),
a lower proportion of patients with diabetes mellitus (OR 0.44,
P 5 0.01), a higher proportion of patients with a previous
transplantation (OR 1.53, P 5 0.04), a longer duration of dialysis
at the time of enrollment (OR 1.004 per month on dialysis, P 5
0.03), and a higher proportion of patients with history of transfu-
sions (OR 4.58, P 5 0.01). The presence of serum GBV-C RNA
was not associated with a significantly increased OR for anti-
HCV. Also, serum GBV-C RNA was not associated with a
significantly increased OR for history of liver disease or NANBH,
or elevated serum alanine aminotransferase (ALT) levels. The
significance of the association between serum GBV-C RNA and
the variables did not change when adjusted for anti-HCV (data not
shown). Likewise, none of the two-way interactions between anti-
HCV and the individual variables was significant (data not shown).
Multivariate analysis. Data on history of blood transfusions was
not available in 44% of patients, and was initially excluded from
the model (Table 3). Among the remaining variables that were
significantly associated with serum GBV-C RNA in the univariate
model, the step-wise multivariate regression model retained only
Table 1. Prevalence of serum anti-HCV and GBV-C RNA among patients referred for renal transplantation
Patient
population Sera availablec
Anti-HCV
positive
Anti-HCV
negative
controls Total
Sera available for
GBV-C RNA
testing
Prevalence of GBV-C RNA
Anti-HCV
positive
Anti-HCV
negative
Overalld
(extrapolated)
Prevalenta 394/655 (60%) 139/394 (35%) 122 261 217/261 (83%) 38/108 (35%) 34/109 (31%) 129/394 (33%)
Incidentb 1150/2588 (44%) 148/1150 (13%) 164 312 248/312 (79%) 33/97 (34%) 41/151 (27%) 322/1150 (28%)
Overall 1544/3243 (48%) 287/1544 (19%) 286 573 465/573 (81%) 71/205 (35%) 75/260 (29%) 451/1544 (29%)
a Patients on the renal transplant waiting list between November, 1986 and January 1987
b Patients referred for renal transplantation between February, 1987 and June, 1990
c For prevalent patients, the first serum sample available during the period between November 1986 and January 1987, and for incident patients, the
first serum sample available within the first six months of referral for transplantation.
d See the section on “Statistical methods’ in the text for calculation of extrapolated prevalence
Table 2. Clinical and laboratory characteristics of patients with and without serum GBV-C RNA at the time of referral for renal transplantationa
Clinical and laboratory characteristics
GBV-C RNA positive GBV-C RNA negative
Odds
ratiob
95% Confidence
intervalsc Pd
Number
(N 5 146)
Median (range)
or percent
Number
(N 5 319)
Median (range)
or percent
Age years 143 38 (5–66) 311 40 (1–76) 0.98e 0.96–0.995 0.01
Gender male 68/145 47 184/318 58 0.64 0.43–0.95 0.03
Race non-white 39/142 27 73/312 23 1.24 0.79–1.95 0.35
History of liver disease 31/132 23 57/295 19 1.28 0.78–2.10 0.33
History of NANBH 11/132 8 15/295 5 1.70 0.76–3.80 0.20
Diabetes mellitus yes 16/141 11 71/314 23 0.44 0.24–0.79 0.01
Prior transplantation yes 64/141 45 108/307 35 1.53 1.02–2.30 0.04
Mode of dialysis number on hemodialysis 118/135 87 255/298 86 1.17 0.64–2.14 0.85
Duration since initiation of RRT months 142 48 (0–240) 316 29 (0–249) 1.004e 1.00–1.007 0.03
History of transfusions 83/86 97 151/176 86 4.58 1.34–15.63 0.01
Hepatitis B serology
HBsAg positive 1/109 1 7/241 3 0.31 0.04–2.55 0.28
Anti-HBs positive 11/64 17 47/167 28 0.53 0.26–1.102 0.09
Anti-HBc positive 0/9 0 11/47 23
Anti-HCV positive 71/146 49 134/319 42 1.31 0.88–1.94 0.18
Anti-CMV positive 43/66 65 84/155 54 1.58 0.87–2.87 0.13
Increased alanine aminotransferase yesf 5/75 13/188 7 0.96 0.33–2.80 0.94
Serum albumin g/dl 91 3.8 (2.6–5.1) 224 3.9 (2.0–5.1) 0.96e 0.62–1.49 0.86
Panel reactive antibody
,10% 21/51 41 46/111 41 1.00 Reference
10–49% 15/51 29 28/111 25 1.17 0.52–2.64 0.60
50–89% 7/51 14 24/111 22 0.64 0.24–1.72
.90% 8/51 16 13/111 12 1.35 0.49–3.74
a Data for continuous variables are presented as median (range) and discrete variables as fraction positive (percent). GBV-C, GB virus C; HCV,
hepatitis C virus; NANBH, non-A, non-B hepatitis; RRT, renal replacement therapy; HBsAg, hepatitis B surface antigen; anti-HBs, antibody to
hepatitis B surface antigen; anti-HBc, antibody to hepatitis B core antigen; CMV, cytomegalovirus.
b Odds ratio of being GBV-C RNA positive
c 95% confidence intervals of the odds ratio
d Logistic regression analysis, p value by Wald Chi-square test
e Odds ratio calculated per year of age, per month of RRT prior to enrollment and per g/dl change in serum albumin concentration
f Serum alanine aminotransferase levels .2.5 times normal
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age, gender and diabetes mellitus. Anti-HCV status was forced
into the model. History of blood transfusions was categorized as
presence, absence or missing data, and included in the final
model. As shown in Table 3, a younger age (OR 0.98 per year of
age, P 5 0.03), and a history of blood transfusions (OR 3.89, P 5
0.03) were associated with an increased OR for serum GBV-C
RNA, while diabetes mellitus was associated with a decreased OR
for GBV-C RNA (OR 0.47, P 5 0.01). Anti-HCV was not a
predictor of serum GBV-C RNA (OR 1.07, P 5 0.77).
DISCUSSION
This study showed that the overall extrapolated prevalence of
serum GBV-C RNA among patients referred for renal transplan-
tation was 29%. The prevalence of serum GBV-C RNA among
anti-HCV positive patients was not significantly different from
that among anti-HCV negative patients. While younger age and
history of blood transfusions was associated with an increased risk
of serum GBV-C RNA, the presence of diabetes mellitus was
associated with a lower risk of serum GBV-C RNA. Interestingly,
GBV-C was not associated with a history, or clinical or laboratory
evidence of liver disease. These results provide further support to
the fact that GBV-C is a parenterally transmitted virus, and shed
light on the modes of transmission among ESRD patients, but
question its role in liver disease.
The modes of transmission of GBV-C infection among dialysis
patients are unclear. We observed a strong association between a
history of blood transfusions and presence of serum GBV-C
RNA. Indeed, patients who had received blood transfusions had a
fourfold higher risk of testing positive for GBV-C RNA in the
serum. These data support the hypothesis that GBV-C is trans-
mitted by blood transfusions. However, the association between
serum GBV-C RNA and other risk factors for parenterally
transmitted viruses such as history of previous transplantation and
duration of dialysis was less certain. Although both these risk
factors were associated with a significantly increased OR for
GBV-C infection in the univariate analysis, neither was significant
in the multivariate analysis, suggesting that they are not indepen-
dent predictors for GBV-C infection. These results are in contrast
to HCV, where duration of dialysis (suggesting nosocomial trans-
mission in dialysis units) and previous organ transplantation
(suggesting transmission from organ donors and/or peri-operative
blood transfusions) have been shown to be independent predic-
tors of HCV infection [31, 33, 34]. Taken together, these data
suggest that the likelihood of acquiring GBV-C infection by
nosocomial transmission in dialysis units or from organ donors is
lower than that from blood transfusions.
The prevalence of serum GBV-C RNA among anti-HCV
positive patients (35%) was not significantly different from that
among anti-HCV negative patients (29%), as reported in our
earlier study [24]. In contrast, among cadaver organ donors we
have previously reported a fourfold higher prevalence of serum
GBV-C RNA among anti-HCV positive donors compared to
anti-HCV negative donors [27]. This suggests that cadaver organ
donors probably acquire GBV-C and HCV together, while dialysis
patients acquire them independently. This difference between the
two populations is probably related to differences in the risk
factors associated with GBV-C infection between the two groups.
Prevalence of serum GBV-C RNA among cadaver organ donors
is associated with high-risk social behavior [27], which probably
results in acquisition of several parenterally transmitted viruses
from the same source. In contrast, among dialysis patients,
prevalence of GBV-C is associated with history of blood transfu-
sions, and healthy blood donors who transmit infections are less
likely to be infected with more than one parenterally transmitted
virus.
The lack of association between GBV-C infection and history
or laboratory evidence of liver disease in the current study
provides support to the growing consensus that GBV-C is not a
hepatotropic virus. Earlier studies that observed a higher preva-
lence of GBV-C RNA among volunteer blood donors with
elevated ALT levels [19], patients with hepatitis of unknown
etiology [35], chronic non-A-E hepatitis [19] and fulminant hep-
atitis [36–38] had suggested that GBV-C may be a hepatotropic
virus. However, several more recent data suggest otherwise. First,
among patients with acute hepatitis due to community-acquired
hepatitis A, B or C infection, biochemical markers of liver disease
were similar among patients with and without HGV infection [28].
Further, the prevalence of chronic hepatitis among patients with
both HCV and HGV infections was similar to that among patients
with HCV infection alone [28]. Second, among blood transfusion
recipients, the prevalence of HGV RNA was not significantly
different between groups with (a) hepatitis C, (b) non-A, non-B,
non-C hepatitis, or (c) no hepatitis [29]. Third, among patients
with fulminant hepatic failure, serum GBV-C RNA was uniformly
absent in blood samples at the time of admission, before any
blood transfusion [39]. Fourth, the prevalence of abnormal liver
function tests was not significantly different between GBV-C
RNA positive and negative cadaver organ donors [27]. Fifth, the
prevalence of abnormal liver function tests among chronic hemo-
dialysis patients was similar among patients with and without
serum GBV-C RNA [18, 23]. Sixth, GBV-C could not be impli-
cated in the etiology of post-transplantation hepatitis among liver
transplant recipients [40–42], or post-transplant liver disease
among renal transplant recipients [24]. Seventh, co-infection with
GBV-C did not affect the severity of liver disease or response to
interferon therapy among patients with chronic HCV induced-
liver disease [43]. Finally, in the current study, the prevalence of
elevated serum ALT levels among GBV-C RNA positive patients
(7%) was not significantly different from that among GBV-C
RNA negative patients (7%). These studies suggest that GBV-C
Table 3. Clinical and laboratory characteristics associated with serum
GBV-C RNA among patients referred for renal transplantationa
Risk factor
Odds
ratiob
95% Confidence
Intervalsc Pd
Age per year 0.98 0.97–0.999 0.03
Gender male 0.69 0.46–1.04 0.08
Diabetes mellitus 0.47 0.26–0.86 0.01
Anti-HCV positive 1.07 0.69–1.64 0.77
History of blood transfusions yese 3.89 1.12–13.58 0.03
Patients with missing data on
history of blood transfusionse
3.17 0.90–11.11 0.07
a In the first serum sample available during the period between Novem-
ber 1986 and January 1987 (prevalent patients) or the first serum sample
available within the first six months of referral for transplantation (inci-
dent patients).
b Odds ratio for being GBV-C RNA positive
c 95% confidence intervals of the odds ratio
d Multivariate logistic regression model, P value by Wald chi-square test
e Compared with patients who did not have blood transfusions prior to
enrollment
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is unlikely to be associated with either acute or chronic liver
disease.
We observed that a younger age and the absence of diabetes
mellitus were predictors for the presence of GBV-C RNA among
patients referred for renal transplantation. The association of
GBV-C RNA and younger age has also been observed among
community-acquired acute hepatitis patients [28], and patients
with chronic liver disease due to HCV [43]. The reason for this
association remains unexplained. The lower prevalence of GBV-C
among diabetics could be attributed to the fact that diabetics were
on dialysis for a shorter duration than non-diabetics (median 15
vs. 46 months, respectively) and consequently may have received
lower number of blood-product transfusions compared to non-
diabetics. However, the actual number of transfusions received by
diabetic and non-diabetic patients could not be reliably deter-
mined, since information on this variable was available in less than
half the study population.
In conclusion, this study provides further evidence that GBV-C
is parenterally transmitted, but questions the role of GBV-C in
the etiology of liver disease among patients referred for renal
transplantation. Further studies are required to determine
whether GBV-C is associated with adverse outcomes after renal
transplantation.
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